{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:11:36Z","timestamp":1791288696124,"version":"4.3.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.toxicon.2012.12.004","type":"journal-article","created":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T17:28:10Z","timestamp":1359998890000},"page":"94-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":200,"special_numbering":"C","title":["Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders"],"prefix":"10.1016","volume":"67","author":[{"given":"Mark","family":"Hallett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2012.12.004_bib3","first-page":"345","article-title":"Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia","volume":"24","author":"Adams","year":"1995","journal-title":"J. Otolaryngol."},{"key":"10.1016\/j.toxicon.2012.12.004_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/mds.20098","article-title":"Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia","volume":"19","author":"Adler","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.parkreldis.2007.10.007","article-title":"Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck","volume":"14","author":"Aguirregomozcorta","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib6","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/000348940010900215","article-title":"Effects of botulinum toxin on pathophysiology in spasmodic dysphonia","volume":"109","author":"Bielamowicz","year":"2000","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"10.1016\/j.toxicon.2012.12.004_bib8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/000348940111000503","article-title":"Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia","volume":"110","author":"Bielamowicz","year":"2001","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"10.1016\/j.toxicon.2012.12.004_bib1","series-title":"Botox [Package Insert]","year":"2010"},{"key":"10.1016\/j.toxicon.2012.12.004_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/IOP.0b013e31819946c4","article-title":"High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference?","volume":"25","author":"Boyle","year":"2009","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2012.12.004_bib10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","article-title":"Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial","volume":"46","author":"Brans","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib11","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib13","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1212\/WNL.56.11.1523","article-title":"A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor","volume":"56","author":"Brin","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib14","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/1531-8257(199903)14:2<307::AID-MDS1016>3.0.CO;2-3","article-title":"Effect of muscle activity immediately after botulinum toxin injection for writer's cramp","volume":"14","author":"Chen","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib15","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/mds.21599","article-title":"Malignant Tourette syndrome","volume":"22","author":"Cheung","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib16","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mds.870100411","article-title":"Double-blind trial of botulinum toxin for treatment of focal hand dystonia","volume":"10","author":"Cole","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.toxicon.2012.12.004_bib19","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clinph.2007.07.004","article-title":"Sensory integration in writer's cramp: comparison with controls and evaluation of botulinum toxin effect","volume":"118","author":"Contarino","year":"2007","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.toxicon.2012.12.004_bib20","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/00005537-199908000-00021","article-title":"Increased stability of airflow following botulinum toxin injection","volume":"109","author":"Finnegan","year":"1999","journal-title":"Laryngoscope"},{"key":"10.1016\/j.toxicon.2012.12.004_bib21","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1212\/WNL.58.12.1843","article-title":"Botulinum toxin improves lid opening in blepharospasm-associated apraxia of lid opening","volume":"58","author":"Forget","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1017\/S0317167100038506","article-title":"Localizing muscles for botulinum toxin treatment of focal hand dystonia","volume":"23","author":"Geenen","year":"1996","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.toxicon.2012.12.004_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0022-510X(97)00151-2","article-title":"The mechanism of action of Botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site","volume":"152","author":"Giladi","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.toxicon.2012.12.004_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.870110107","article-title":"Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study","volume":"11","author":"Girlanda","year":"1996","journal-title":"Mov. Disord."},{"issue":"Suppl. 8","key":"10.1016\/j.toxicon.2012.12.004_bib25","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1002\/mds.20065","article-title":"Physiological effects of botulinum toxin in spasticity","volume":"19","author":"Gracies","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/1531-8249(200007)48:1<7::AID-ANA2>3.0.CO;2-O","article-title":"How does botulinum toxin work?","volume":"48","author":"Hallett","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.toxicon.2012.12.004_bib27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/jnnp.60.6.704","article-title":"Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening","volume":"60","author":"Jankovic","year":"1996","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.toxicon.2012.12.004_bib28","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/mds.870110306","article-title":"A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor","volume":"11","author":"Jankovic","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib30","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp.2005.083170","article-title":"Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up","volume":"78","author":"Kruisdijk","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.toxicon.2012.12.004_bib32","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archneur.57.8.1190","article-title":"Botulinum toxin in the treatment of tics","volume":"57","author":"Kwak","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.toxicon.2012.12.004_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/PHM.0b013e3181bc0c78","article-title":"Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial","volume":"89","author":"Lee","year":"2010","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.toxicon.2012.12.004_bib34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"Lew","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib35","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1212\/WNL.38.8.1220","article-title":"Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia","volume":"38","author":"Ludlow","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1212\/WNL.56.5.605","article-title":"Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial","volume":"56","author":"Marras","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1047-9651(03)00093-7","article-title":"Muscle overactivity and movement dysfunction in the upper motoneuron syndrome","volume":"14","author":"Mayer","year":"2003","journal-title":"Phys. Med. Rehabil. Clin. N. Am."},{"key":"10.1016\/j.toxicon.2012.12.004_bib38","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.58.5.805","article-title":"Accuracy of muscle localization without EMG: implications for treatment of limb dystonia","volume":"58","author":"Molloy","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","article-title":"Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm","volume":"235","author":"Nussgens","year":"1997","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.toxicon.2012.12.004_bib40","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/mds.1226","article-title":"Cervical dystonia severity scale reliability study","volume":"16","author":"O'Brien","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib41","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.parkreldis.2007.03.006","article-title":"Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm","volume":"13","author":"Ochudlo","year":"2007","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","article-title":"A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia","volume":"64","author":"Odergren","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.toxicon.2012.12.004_bib43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1212\/WNL.45.4.822","article-title":"Botulinum toxin treatment of essential head tremor","volume":"45","author":"Pahwa","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib45","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3346\/jkms.1993.8.5.334","article-title":"Botulinum a toxin treatment of hemifacial spasm and blepharospasm","volume":"8","author":"Park","year":"1993","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.toxicon.2012.12.004_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","article-title":"What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group","volume":"64","author":"Poewe","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.toxicon.2012.12.004_bib47","first-page":"459","article-title":"Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia","volume":"72","author":"Ranoux","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.toxicon.2012.12.004_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of a new botulinum toxin Type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenkamper","year":"2006","journal-title":"J. Neural Transm."},{"issue":"Suppl. 1","key":"10.1016\/j.toxicon.2012.12.004_bib49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1468-1331.2010.03056.x","article-title":"On muscle spindles, dystonia and botulinum toxin","volume":"17","author":"Rosales","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2012.12.004_bib50","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","article-title":"DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2013dysport and botox\u2013assuming a ratio of 4:1","volume":"12","author":"Sampaio","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib51","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1586\/14737175.3.6.773","article-title":"Botulinum toxin treatment of adult spasticity","volume":"3","author":"Sheean","year":"2003","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.toxicon.2012.12.004_bib52","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib53","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/mds.21435","article-title":"Botulinum toxin type B (Myobloc) in subjects with hemifacial spasm: results from an open-label, dose-escalation safety study","volume":"22","author":"Trosch","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1288\/00005537-199106000-00010","article-title":"Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia","volume":"101","author":"Troung","year":"1991","journal-title":"Laryngoscope"},{"key":"10.1016\/j.toxicon.2012.12.004_bib55","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib56","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","article-title":"Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial","volume":"14","author":"Truong","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib57","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia","volume":"16","author":"Truong","year":"2010","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.43.1_Part_1.183","article-title":"Botulinum toxin in the treatment of writer's cramp: a double-blind study","volume":"43","author":"Tsui","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib59","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","article-title":"Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm","volume":"118","author":"Wabbels","year":"2011","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.toxicon.2012.12.004_bib60","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1097\/00005537-200008000-00028","article-title":"Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection","volume":"110","author":"Warrick","year":"2000","journal-title":"Laryngoscope"},{"key":"10.1016\/j.toxicon.2012.12.004_bib61","first-page":"209","article-title":"Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia","volume":"24","author":"Wong","year":"1995","journal-title":"J. Otolaryngol."},{"key":"10.1016\/j.toxicon.2012.12.004_bib2","series-title":"Xeomin [Package Insert]","year":"2010"},{"key":"10.1016\/j.toxicon.2012.12.004_bib62","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/mds.23692","article-title":"The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms","volume":"26","author":"Yaltho","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2012.12.004_bib63","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.42.3.627","article-title":"Botulinum toxin therapy for limb dystonias","volume":"42","author":"Yoshimura","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2012.12.004_bib64","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/mus.880150909","article-title":"Treatment of hemifacial spasm with botulinum toxin","volume":"15","author":"Yoshimura","year":"1992","journal-title":"Muscle Nerve"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010112008276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010112008276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T13:20:56Z","timestamp":1714915256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010112008276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":64,"alternative-id":["S0041010112008276"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2012.12.004","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2012.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}